On Nov. 6, 2026 Moderna reported third-quarter revenue of $1.313 billion, which its headline rounds to $1.3 billion, and GAAP net income of $162 million, or $0.38 diluted. Revenue was $780 million in the United States and $533 million outside it, and the company raised 2026 revenue-growth guidance to 15 to 25 percent from up to 10 percent. Cash, cash equivalents, and investments were $7.976 billion at Sept. 30 on the balance-sheet lines, which the release rounds to $8.0 billion.
/ Sources
/ About this story
Compiled by Venture Atlas from the sources above, using automated AI-assisted research. This is a summary of reporting published elsewhere, not original reporting - follow the source links for the full account. See our editorial standards.
Something wrong here? Email apostructura@gmail.com and we will fix it.
/ Related
- Health Canada authorizes Moderna's mRNA flu and flu-COVID vaccinesFriday, November 6, 2026
- WHO advisers recommend Moderna's Bundibugyo shot for trialThursday, November 5, 2026
- UK MHRA authorizes Moderna XFG Spikevax updateMonday, September 7, 2026
- Moderna prices upsized $2.6 billion convertible notesTuesday, September 1, 2026
